The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Benign Prostatic Hyperplasia Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease
The global Benign Prostatic Hyperplasia Therapeutics market size is expected to reach US$ 8438.6 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Benign Prostatic Hyperplasia Therapeutics in various end use industries. The expanding demands from the Mono Drug Therapy and Combination Drug Therapy, are propelling Benign Prostatic Hyperplasia Therapeutics market. Alpha Blocker, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 5-Alpha Reductase Inhibitor segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Benign Prostatic Hyperplasia Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Benign Prostatic Hyperplasia Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Benign Prostatic Hyperplasia Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Benign Prostatic Hyperplasia Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Benign Prostatic Hyperplasia Therapeutics covered in this report include Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH and Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck and Co., Pfizer and Sanofi, etc.
The global Benign Prostatic Hyperplasia Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Global Benign Prostatic Hyperplasia Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Benign Prostatic Hyperplasia Therapeutics market, Segment by Type:
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Global Benign Prostatic Hyperplasia Therapeutics market, by Application
Mono Drug Therapy
Combination Drug Therapy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Benign Prostatic Hyperplasia Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease
The global Benign Prostatic Hyperplasia Therapeutics market size is expected to reach US$ 8438.6 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Benign Prostatic Hyperplasia Therapeutics in various end use industries. The expanding demands from the Mono Drug Therapy and Combination Drug Therapy, are propelling Benign Prostatic Hyperplasia Therapeutics market. Alpha Blocker, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 5-Alpha Reductase Inhibitor segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Benign Prostatic Hyperplasia Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Benign Prostatic Hyperplasia Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Benign Prostatic Hyperplasia Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Benign Prostatic Hyperplasia Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Benign Prostatic Hyperplasia Therapeutics covered in this report include Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH and Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck and Co., Pfizer and Sanofi, etc.
The global Benign Prostatic Hyperplasia Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Global Benign Prostatic Hyperplasia Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Benign Prostatic Hyperplasia Therapeutics market, Segment by Type:
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Global Benign Prostatic Hyperplasia Therapeutics market, by Application
Mono Drug Therapy
Combination Drug Therapy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Benign Prostatic Hyperplasia Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Benign Prostatic Hyperplasia Therapeutics
1.1 Benign Prostatic Hyperplasia Therapeutics Market Overview
1.1.1 Benign Prostatic Hyperplasia Therapeutics Product Scope
1.1.2 Benign Prostatic Hyperplasia Therapeutics Market Status and Outlook
1.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2018-2029)
1.4 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Benign Prostatic Hyperplasia Therapeutics Market Size (2018-2029)
1.6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size (2018-2029)
1.6.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (2018-2029)
1.6.4 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size (2018-2029)
2 Benign Prostatic Hyperplasia Therapeutics Market by Type
2.1 Introduction
2.1.1 Alpha Blocker
2.1.2 5-Alpha Reductase Inhibitor
2.1.3 Phosphodiesterase-5 Inhibitor
2.1.4 Others
2.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Type (2018-2029)
3 Benign Prostatic Hyperplasia Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Mono Drug Therapy
3.1.2 Combination Drug Therapy
3.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Breakdown by Application (2018-2029)
4 Benign Prostatic Hyperplasia Therapeutics Competition Analysis by Players
4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2022)
4.3 Date of Key Players Enter into Benign Prostatic Hyperplasia Therapeutics Market
4.4 Global Top Players Benign Prostatic Hyperplasia Therapeutics Headquarters and Area Served
4.5 Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Benign Prostatic Hyperplasia Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Profile
5.1.2 Abbott Laboratories Main Business
5.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.1.4 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Laboratories Recent Developments
5.2 Allergan plc
5.2.1 Allergan plc Profile
5.2.2 Allergan plc Main Business
5.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.2.4 Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Allergan plc Recent Developments
5.3 Astellas Pharma
5.3.1 Astellas Pharma Profile
5.3.2 Astellas Pharma Main Business
5.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.3.4 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
5.4 Boehringer Ingelheim Pharma GmbH and Co. KG
5.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Profile
5.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Main Business
5.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
5.5 Eli Lilly and Company
5.5.1 Eli Lilly and Company Profile
5.5.2 Eli Lilly and Company Main Business
5.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.5.4 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Eli Lilly and Company Recent Developments
5.6 GlaxoSmithKline plc
5.6.1 GlaxoSmithKline plc Profile
5.6.2 GlaxoSmithKline plc Main Business
5.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.6.4 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline plc Recent Developments
5.7 Merck and Co.
5.7.1 Merck and Co. Profile
5.7.2 Merck and Co. Main Business
5.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.7.4 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Merck and Co. Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.8.4 Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
5.9 Sanofi
5.9.1 Sanofi Profile
5.9.2 Sanofi Main Business
5.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.9.4 Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Sanofi Recent Developments
5.10 Teva Pharmaceutical Industries Limited
5.10.1 Teva Pharmaceutical Industries Limited Profile
5.10.2 Teva Pharmaceutical Industries Limited Main Business
5.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
5.10.4 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Teva Pharmaceutical Industries Limited Recent Developments
6 North America
6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Benign Prostatic Hyperplasia Therapeutics Market Dynamics
11.1 Benign Prostatic Hyperplasia Therapeutics Industry Trends
11.2 Benign Prostatic Hyperplasia Therapeutics Market Drivers
11.3 Benign Prostatic Hyperplasia Therapeutics Market Challenges
11.4 Benign Prostatic Hyperplasia Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
